These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


423 related items for PubMed ID: 10877911

  • 1. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
    Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P.
    Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
    [Abstract] [Full Text] [Related]

  • 2. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA, Su C.
    Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
    [Abstract] [Full Text] [Related]

  • 3. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [Abstract] [Full Text] [Related]

  • 4. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):155-61. PubMed ID: 15790539
    [Abstract] [Full Text] [Related]

  • 5. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ, Snyder RO, Leff SE.
    Exp Neurol; 1999 Nov 24; 160(1):205-14. PubMed ID: 10630205
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.
    Natsume A, Mata M, Goss J, Huang S, Wolfe D, Oligino T, Glorioso J, Fink DJ.
    Exp Neurol; 2001 Jun 24; 169(2):231-8. PubMed ID: 11358438
    [Abstract] [Full Text] [Related]

  • 9. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
    Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K.
    Gene Ther; 2002 Mar 24; 9(6):381-9. PubMed ID: 11960314
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC.
    Gene Ther; 1999 Dec 24; 6(12):1936-51. PubMed ID: 10637445
    [Abstract] [Full Text] [Related]

  • 11. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2000 Nov 24; 166(1):1-15. PubMed ID: 11031079
    [Abstract] [Full Text] [Related]

  • 12. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
    Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Chtarto A, Levivier M, Brotchi J, Michotte Y, Baekelandt V, Sarre S, Tenenbaum L.
    J Gene Med; 2009 Oct 24; 11(10):899-912. PubMed ID: 19639608
    [Abstract] [Full Text] [Related]

  • 13. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ.
    Brain Res; 2000 Dec 15; 886(1-2):82-98. PubMed ID: 11119690
    [Abstract] [Full Text] [Related]

  • 14. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease.
    Törnqvist N, Björklund L, Almqvist P, Wahlberg L, Strömberg I.
    Exp Neurol; 2000 Jul 15; 164(1):130-8. PubMed ID: 10877923
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
    Lo Bianco C, Déglon N, Pralong W, Aebischer P.
    Neurobiol Dis; 2004 Nov 15; 17(2):283-9. PubMed ID: 15474365
    [Abstract] [Full Text] [Related]

  • 19. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
    Bowenkamp KE, Lapchak PA, Hoffer BJ, Miller PJ, Bickford PC.
    Exp Neurol; 1997 May 15; 145(1):104-17. PubMed ID: 9184114
    [Abstract] [Full Text] [Related]

  • 20. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C, Kirik D, Björklund A.
    Exp Neurol; 2000 Feb 15; 161(2):503-16. PubMed ID: 10686072
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 22.